These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18832842)

  • 41. Reflux inhibitors: a new approach for GERD?
    Boeckxstaens GE
    Curr Opin Pharmacol; 2008 Dec; 8(6):685-9. PubMed ID: 18771751
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Gastroesophageal reflux and esophagitis (II). Treatment guidelines].
    Velasco A; Alvarez FJ
    Rev Esp Enferm Dig; 1991 Jun; 79(6):416-23. PubMed ID: 1910920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Health economy assessments--how to find them].
    Alton V; Eckerlund I; Norlund A
    Lakartidningen; 2006 May 31-Jun 6; 103(21-22):1726-33. PubMed ID: 16826717
    [No Abstract]   [Full Text] [Related]  

  • 44. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
    Beaumont H; Boeckxstaens GE
    Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic evaluations of gastroesophageal reflux disease medical management.
    Gawron AJ; French DD; Pandolfino JE; Howden CW
    Pharmacoeconomics; 2014 Aug; 32(8):745-58. PubMed ID: 24807469
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of gluten-free diet on preventing recurrence of gastroesophageal reflux disease-related symptoms in adult celiac patients with nonerosive reflux disease.
    Usai P; Manca R; Cuomo R; Lai MA; Russo L; Boi MF
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1368-72. PubMed ID: 18853995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased swallowing frequency in GORD is likely to be caused by perception of reflux episodes.
    Hemmink GJ; Weusten BL; Bredenoord AJ; Timmer R; Smout AJ
    Neurogastroenterol Motil; 2009 Feb; 21(2):143-8. PubMed ID: 19019017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis.
    Spechler SJ; Genta RM; Souza RF
    Am J Gastroenterol; 2007 Jun; 102(6):1301-6. PubMed ID: 17531015
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected].
    Heidelbaugh JJ; Goldberg KL; Inadomi JM
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S27-32. PubMed ID: 19262544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reducing the cost of proton pump inhibitors by adopting best practice.
    Hughes JD; Tanpurekul W; Keen NC; Ee HC
    Qual Prim Care; 2009; 17(1):15-21. PubMed ID: 19281670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of lifestyle modification on the health-related quality of life of patients with reflux esophagitis receiving treatment with a proton pump inhibitor.
    Kinoshita Y; Ashida K; Miwa H; Hongo M
    Am J Gastroenterol; 2009 May; 104(5):1106-11. PubMed ID: 19337239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):21-2. PubMed ID: 19305367
    [No Abstract]   [Full Text] [Related]  

  • 53. Review article: The laryngological manifestations of reflux disease; why the scepticism?
    Mahieu HF
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():17-24. PubMed ID: 18081645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Gastroesophageal reflux disease--diagnosis and management].
    Wojtuń S; Gil J; Jałocha Ł; Błaszak A; Wojtkowiak M
    Pol Merkur Lekarski; 2009 May; 26(155):512-6. PubMed ID: 19606713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of pathological duodenogastric reflux and the relationship between duodenogastric and duodenogastrooesophageal reflux in chronic gastrooesophageal reflux disease.
    Brillantino A; Monaco L; Schettino M; Torelli F; Izzo G; Cosenza A; Marano L; Di Martino N
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1136-43. PubMed ID: 18946360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of heartburn not responding to proton pump inhibitors.
    Fass R; Sifrim D
    Gut; 2009 Feb; 58(2):295-309. PubMed ID: 19136523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. On-demand therapy for gastroesophageal reflux disease.
    Metz DC; Inadomi JM; Howden CW; van Zanten SJ; Bytzer P
    Am J Gastroenterol; 2007 Mar; 102(3):642-53. PubMed ID: 17156134
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical treatment of gastroesophageal reflux disease in the managed care environment.
    Fennerty MB
    Semin Gastrointest Dis; 1997 Apr; 8(2):90-9. PubMed ID: 9109696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High economic burden of caring for patients with suspected extraesophageal reflux.
    Francis DO; Rymer JA; Slaughter JC; Choksi Y; Jiramongkolchai P; Ogbeide E; Tran C; Goutte M; Garrett CG; Hagaman D; Vaezi MF
    Am J Gastroenterol; 2013 Jun; 108(6):905-11. PubMed ID: 23545710
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of alginic acid in combination with proton pump inhibitor for the treatment of gastroesophageal reflux disease in systemic sclerosis patients.
    Foocharoen C; Kingkaew P; Teerawattananon Y; Mahakkanukrauh A; Suwannaroj S; Manasirisuk W; Chaiyarit J; Sangchan A
    Int J Rheum Dis; 2023 Oct; 26(10):2037-2046. PubMed ID: 37665078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.